SCHEMBL25544776

SCHEMBL25544776

Cc1ccc2c(-c3ccc(F)cc3)c(C3CCOCC3)cnc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 5/20 0.37
PIK3CB P42338 2/20 0.37
PRKDC P78527 2/20 0.37
ATR Q13535 2/20 0.37
ATRIP Q8WXE1 2/20 0.37
ATM Q13315 1/20 0.36
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
MAPK14 Q16539 1/20 0.35
GRM2 Q14416 1/20 0.35
RPS6KA3 P51812 1/20 0.35
DRD2 P14416 1/20 0.34
HTR1B P28222 1/20 0.34
HTR6 P50406 1/20 0.34
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544354 0.88 GRIN2B (0.41) PIK3CBPRKDCATRATRIPATM
SCHEMBL25544779 0.86 RPS6KA3 (0.40) GRM5PIK3CAMAPK14RPS6KA3HDAC1
SCHEMBL25557661 0.78 PARP14 (0.44) PRKDC
SCHEMBL25544319 0.77 GRM2 (0.38) GRM2
SCHEMBL25544311 0.77 GRM2 (0.41) GRM2
SCHEMBL23888050 0.77 GRIN2B (0.40) PIK3CBPRKDCATRATRIPRPS6KA3
SCHEMBL25544651 0.77 ABL1 (0.36) PIK3CAMTORPDE1APDE1BPDE1C
SCHEMBL25544773 0.75 SLC6A2 (0.32) RPS6KA3DRD2SLC6A2SLC6A4SLC6A3
SCHEMBL25544321 0.72 GRM5 (0.43) GRM5PIK3CAGRM2
SCHEMBL25544752 0.72 MAPK14 (0.39) GRM5PIK3CBPRKDCATRATRIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 GRM5 4601/4885PIK3CB 3961/4885PRKDC 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.